 |
|
Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005
Paul M Ridker, MD;
Jose Torres, BA
JAMA. 2006;295:2270-2274.
Context In surveys based on data available prior to 2000, clinical trials funded by for-profit organizations appeared more likely to report positive findings than those funded by not-for-profit organizations. Whether this situation has changed over the past 5 years or whether similar effects are present among jointly funded trials is unknown.
Objective To determine in contemporary randomized cardiovascular trials the association between funding source and the likelihood of reporting positive findings.
Design We reviewed 324 consecutive superiority trials of cardiovascular medicine published between January 1, 2000, and July 30, 2005, in JAMA, The Lancet, and the New England Journal of Medicine.
Main Outcome Measure The proportion of trials favoring newer treatments over the standard of care was evaluated by funding source.
Results Of the 324 superiority trials, 21 cited no funding source. Of the 104 trials funded solely by not-for-profit organizations, 51 (49%) reported evidence significantly favoring newer treatments over the standard of care, whereas 53 (51%) did not (P = .80). By contrast, 92 (67.2%) of 137 trials funded solely by for-profit organizations favored newer treatments over standard of care (P<.001). Among 62 jointly funded trials, 35 (56.5%), an intermediate proportion, favored newer treatments. For 205 randomized trials evaluating drugs, the proportions favoring newer treatments were 39.5%, not-for-profit; 54.4%, jointly funded; and 65.5%, for-profit trials (P for trend across groups = .002). For the 39 randomized trials evaluating cardiovascular devices, the proportions favoring newer treatments were 50.0%, not-for-profit; 69.2%, jointly funded; and 82.4%, for-profit trials (P for trend across groups = .07). Regardless of funding source, trials using surrogate end points, such as quantitative angiography, intravascular ultrasound, plasma biomarkers, and functional measures were more likely to report positive findings (67%) than trials using clinical end points (54.1%; P = .02).
Conclusions Recent cardiovascular trials funded by for-profit organizations are more likely to report positive findings than trials funded by not-for-profit organizations, as are trials using surrogate rather than clinical end points. Trials jointly funded by not-for-profit and for-profit organizations appear to report positive findings at a rate approximately midway between rates observed in trials supported solely by one or the other of these entities.
Author Affiliations: Center for Cardiovascular Disease Prevention and the Divisions of Preventive Medicine and Cardiology, Brigham and Women's Hospital (Dr Ridker), and the Harvard Medical School (Dr Ridker and Mr Torres), Boston, Mass.
RELATED LETTERS
Incomplete Financial Disclosure for Study of Funding and Outcomes in Major Cardiovascular Trials
Paul M Ridker
JAMA. 2006;295(23):2725-2726.
EXTRACT
| FULL TEXT
Funding of Clinical Trials
Steven Borzak
JAMA. 2006;296(16):1969.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2007;50:2254-2262.
FULL TEXT
Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology
Riechelmann et al.
JCO 2007;25:4642-4647.
ABSTRACT
| FULL TEXT
Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect?
Goldberg et al.
Arch Gen Psychiatry 2007;64:1115-1122.
ABSTRACT
| FULL TEXT
Quality of Prospective Controlled Randomized Trials. Analysis of Trials of Treatment for Lateral Epicondylitis as an Example
Cowan et al.
JBJS 2007;89:1693-1699.
ABSTRACT
| FULL TEXT
Update in Critical Care 2006
Milbrandt et al.
Am. J. Respir. Crit. Care Med. 2007;175:638-648.
FULL TEXT
The Legal and Ethical Issues Surrounding Financial Conflict of Interest in Orthopaedic Research
Okike and Kocher
JBJS 2007;89:910-913.
FULL TEXT
Clinical Trial Registration Promotes Patient Protection and Benefit, Advances the Trust of Everyone, and Is Required
Irwin
Chest 2007;131:639-641.
FULL TEXT
Interactions Between Physicians and Industry: A Guide for Clinicians
Jibson
Focus 2007;5:398-406.
ABSTRACT
| FULL TEXT
Funding of clinical trials.
Borzak
JAMA 2006;296:1969-1969.
FULL TEXT
Abstract Acceptance and Blinded Peer Review--Reply
Ross and Krumholz
JAMA 2006;296:1230-1231.
FULL TEXT
For-Profit vs. Not-for-Profit Funding of Cardiovascular Trials
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT
|
